Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Zobel_et_al-2019-Diabetes,_Obesity_and_Metabolism (1)
Final published version, 422 KB, PDF document
Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated individual responses to liraglutide in six cardio-renal risk factors to examine whether responses in one risk factor are associated with changes in other risk factors (cross-dependency). We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes. HbA1c, body weight, systolic blood pressure (SBP) , low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and after 26 weeks of liraglutide/placebo treatment: “Good responders” had a change within the best quartile. In the liraglutide-treated group, good HbA1c responders showed similar changes in other risk factors analysed to low responders (P ≥ 0.17). Good body weight responders had a larger reduction in HbA1c than low body weight responders (−1.6 ± 0.94 vs. –1.0 ± 0.82%; P = 0.003), but similar changes in the other risk factors (P ≥ 0.11). Good and low responders in SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors (P ≥ 0.07). Treatment response to liraglutide is largely individual; aside from an association between body weight and HbA1c reduction, there are no obvious cross-dependencies in risk factor response.
Original language | English |
---|---|
Journal | Diabetes, Obesity and Metabolism |
Volume | 21 |
Issue number | 5 |
Pages (from-to) | 1261-1265 |
ISSN | 1462-8902 |
DOIs | |
Publication status | Published - 2019 |
- diabetic nephropathy, liraglutide, type 2 diabetes
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 223516578